The next generation biopharmaceuticals

Notice to attend Annual General Meeting

2020-05-25

Notice to attend Annual General Meeting

The shareholders of Affibody Medical AB are hereby invited to attend the annual general meeting of the shareholders on Tuesday 23 June 2020, at 2 pm, to be held in company’s premises, Scheeles väg 2, Solna.

Right to participate

Shareholders who wish to participate at the general meeting must be recorded in the share register kept by Euroclear Sweden AB on Tuesday 16 June 2020. Shareholders whose shares are registered in the name of a nominee must temporarily register the shares in their own name. Such registration must be completed by 16 June 2020. Shareholders are therefore advised to request such registration of the shares well in advance of this date.

Shareholders must, in order to participate at the general meeting, also notify their intention to participate to the company no later than Thursday 18 June 2020. Notification shall be done in writing by letter addressed to Affibody Medical AB (publ), Scheeles väg 2, 171 65 Solna or by phone +46 8 59 88 38 00, by fax +46 8 59 88 38 01 or by e-mail to johan.stuart@affibody.se. The notification shall include the shareholder’s name, address, telephone number, e-mail address, social security or corporate identity numbers and the number of shares held. Shareholders or proxies may bring up to two advisors to the general meeting, but only if the shareholders have notified the number of advisors to the company as set out above.

Shareholders represented by proxy shall issue a written and dated power of attorney for the proxy. The power of attorney must not be issued prior to five years before the date of the meeting. The power of attorney in original form, together with appropriate documents evidencing authority for corporate entities, should be provided to the company at the above address.


Proposed agenda

  1. Opening of the meeting and election of a chairman for the meeting.
  2. Preparation and approval of the voting list.
  3. Approval of the agenda.
  4. Election of one or two persons to verify the minutes of the meeting.
  5. Determination of whether the meeting was duly convened.
  6. Submission of the annual report and the auditor’s report, as well as the consolidated annual report and the consolidated auditor’s report.
  7. Decisions regarding
    1. adoption of income statement and balance sheet as well as the consolidated income statement and the consolidated balance sheet,
    2. allocation of the company’s result, and 
    3. discharge from liability for the members of the board of directors and the managing director.
  8. Determining the fees for the members of the board of directors and the auditor.
  9. Election of the members of the board of directors
  10. Election of auditor.
  11. Closing of the meeting.


Proposed resolutions

Items 8, 9 and 10 (Fees and election of board of directors and auditor)

Shareholders representing more than half of the total number of shares and votes propose a fee to the chairman of the board of SEK 500 000 and to other directors of SEK 150 000 each. As per 1 January 2021 the fee to the other directors is proposed to be raised to SEK 250 000 on an annual basis. These shareholders also propose re-election of the directors Robert Burns (chairman), Gillian M. Cannon, Jonathan Knowles, Jakob Lindberg, Mathias Uhlén and José F. Suarez.

Auditor’s fees are proposed to be on current account. The auditing company Ernst & Young AB is proposed as auditor for the period until the end of the annual general meeting 2021. Anna Svanberg will in such an event continue as responsible auditor.

Number of shares and votes

At the time of issuing this notice the total number of shares and votes in the company amounts to 19 879 494.


The shareholders’ right to information and provision of documents

Upon request by any shareholder and where the board of directors believes that such may take place without significant harm to the company, the board of directors shall provide informaton in respect of any circumstances which may affect the assessment of a matter on the agenda or the company’s financial position as well as the company’s relationship to other group companies.

The annual report as well as the auditor’s report for the financial year 2019 and a proxy form will be available no later than Tuesday 2 June 2020 at the company’s office and the company’s website, www.affibody.se, and will also be sent to shareholders who request this and state their address.

In connection with the general meeting personal data will be processed in accordance with the company’s privacy policy, which is available at the company’s website www.affibody.se.

Stockholm in May 2020

Affibody Medical AB (publ)

The Board of Directors

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)